Press Releases
Atamyo Therapeutics Announces participations in Conferences and Key Scientific Communications on its LGMD programs
Participation in Chardan’s 7th Genetic Medicines Conference Participation in Cell and Gene Therapy on the Mesa 2023 Meeting Five upcoming communications on LGMD programs at WMS congress, ESGCT annual meeting and 2023 International Limb-Girdle Muscular […]
Read moreATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, reaches key milestones with the filing of a clinical trial application in Europe and a non-dilutive financing from France 2030 program
A multicenter phase 1b study will evaluate safety, pharmacodynamic and efficacy of ATA-200 ATA-200 is the second Atamyo’s next generation gene replacement therapy entering the clinic ATA-200 is eligible to receive up to €8m ($8.6m) […]
Read moreATA-200, thérapie génique développée par Atamyo et destinée au traitement de la dystrophie musculaire des ceintures de type 2C/R5, franchit des étapes clés avec le dépôt d’une demande d’essai clinique en Europe et un financement non-dilutif du programme France 2030
Étude multicentrique de phase 1b évaluant l’innocuité, la pharmacodynamie et l’efficacité de l’ATA-200 ATA-200 est la deuxième thérapie génique de nouvelle génération d’Atamyo entrant en phase clinique ATA-200 est lauréat de l’appel à projets « […]
Read moreIND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA
LGMD 2I/R9 is a rare muscle dystrophy with no approved treatment ATA-100 is being evaluated in Europe in a multi-center phase 1b/2b Evry, France (September 5, 2023) – Atamyo Therapeutics, a biotechnology company focused on […]
Read moreGene Therapy Pioneer Roger Hajjar, MD, Joins Atamyo Therapeutics Board of Directors
Evry, France (July 24, 2023) – Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced the appointment of Roger J. Hajjar, MD, Director of […]
Read moreAtamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial
• First patient dosed with ATA-100 gene replacement therapy for LGMD-R9• On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 Evry, France (September 26, 2022) – Atamyo Therapeutics, a biotechnology company focused […]
Read moreAtamyo Therapeutics annonce le traitement d’un premier patient avec sa thérapie génique ATA-100 dans l’essai clinique ciblant la myopathie des ceintures LGMD-R9
• Premier patient recevant la thérapie ATA-100 (AAV9-FKRP) pour LGMD-R9 • Étude multicentrique de phase 1-2 en cours évaluant l’innocuité, la pharmacodynamie et l’efficacité de l’ATA-100 Evry, France (26 septembre 2022) – Atamyo Therapeutics, une […]
Read moreAtamyo Therapeutics Announces Key Scientific Communications on Its LGMD Programs
Five scientific publications in key conferences Since June 2022 Four upcoming communications on LGMD-R9 program at Myology 2022 Evry, France (September 6, 2022) – Atamyo Therapeutics, a biotechnology company focused on the development of new-generation […]
Read moreAtamyo Therapeutics annonce des présentations scientifiques clés sur ses programmes LGMD
Cinq présentations scientifiques sur les programmes LGMD depuis juin 2022 Quatre communications sur le programme LGMD-R9 seront présentées au congrès Myology 2022 Evry, France (6 septembre 2022) – Atamyo Therapeutics, une biotech spécialisée dans le […]
Read moreAtamyo Therapeutics announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
Additional approval of Clinical Trial Application for ATA-100 received from French National Medicines Health Agency (ANSM) Orphan Drug Designation awarded from European EMA for ATA-200 Forthcoming presentation on ATA-200 at ASGCT annual meeting Appointment of […]
Read more